PMC:7346000 / 1379-1668 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"27","span":{"begin":32,"end":42},"obj":"Species"},{"id":"31","span":{"begin":85,"end":99},"obj":"Chemical"},{"id":"32","span":{"begin":129,"end":134},"obj":"Chemical"}],"attributes":[{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Tax:2697049"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:D000666"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:D001393"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"al tropism and damage caused by SARS-CoV-2, which may challenge the use of liposomal amphotericin B, as well as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinet"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T21","span":{"begin":32,"end":40},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"al tropism and damage caused by SARS-CoV-2, which may challenge the use of liposomal amphotericin B, as well as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinet"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":98,"end":99},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"al tropism and damage caused by SARS-CoV-2, which may challenge the use of liposomal amphotericin B, as well as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinet"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":85,"end":99},"obj":"Chemical"},{"id":"T7","span":{"begin":129,"end":134},"obj":"Chemical"},{"id":"T8","span":{"begin":196,"end":212},"obj":"Chemical"},{"id":"T10","span":{"begin":207,"end":212},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_2682"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_68452"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"},{"id":"A9","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_86327"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"al tropism and damage caused by SARS-CoV-2, which may challenge the use of liposomal amphotericin B, as well as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinet"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":3,"end":10},"obj":"http://purl.obolibrary.org/obo/GO_0009606"}],"text":"al tropism and damage caused by SARS-CoV-2, which may challenge the use of liposomal amphotericin B, as well as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinet"}